Neogen/$NEOG
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Neogen
Neogen Corp is develop, manufacture and market a diverse line of products and services dedicated to food and animal safety. Its Food Safety segment consists mainly of diagnostic test kits and complementary products (e.g., culture media) sold to food and animal feed producers and processors to preserve the safety and quality of food to prevent contamination and foodborne illnesses such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, and ruminant by-products. These products also ensure the general hygiene of the food manufacturing environment. It also have products to determine food quality and nutritional components. Its segments are Food, Animal safety. Majority of revenue comes from Food Safety. It has presence in United states, and International market.
- Ticker
- $NEOG
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,636
- Headquarters
- Lansing, United States
- Website
- www.neogen.com
Neogen Metrics
BasicAdvanced
$2.6B
-
-$0.26
1.79
-
Price and volume
Market cap
$2.6B
Beta
1.79
52-week high
$14.26
52-week low
$5.37
Average daily volume
4.5M
Financial strength
Current ratio
3.896
Quick ratio
2.062
Long term debt to equity
0.371
Total debt to equity
0.371
Interest coverage (TTM)
-0.13%
Profitability
EBITDA (TTM)
109
Gross margin (TTM)
47.40%
Net profit margin (TTM)
-6.35%
Operating margin (TTM)
-0.83%
Effective tax rate (TTM)
17.13%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
-0.14%
Return on equity (TTM)
-2.67%
Valuation
Price to revenue (TTM)
2.911
Price to book
1.24
Price to tangible book (TTM)
-10.03
Price to free cash flow (TTM)
51.677
Free cash flow yield (TTM)
1.94%
Free cash flow per share (TTM)
0.229
Growth
Revenue change (TTM)
-0.33%
Earnings per share change (TTM)
-94.60%
3-year revenue growth (CAGR)
-1.29%
10-year revenue growth (CAGR)
10.35%
3-year earnings per share growth (CAGR)
28.28%
10-year earnings per share growth (CAGR)
-3.41%
What the Analysts think about Neogen
Analyst ratings (Buy, Hold, Sell) for Neogen stock.
Analyst projections of the future price of Neogen stock.
Bulls say / Bears say
First-quarter revenue rose 6.5%, with core growth of 8.1% in both Food Safety and Animal Safety; Neogen also raised its FY27 revenue and adjusted EBITDA guidance. This points to a broadening recovery, although some of the quarter’s core growth came from order timing and distributor inventory effects. (Neogen Corporation)
Adjusted EBITDA margin increased to 18.7% from 17.0% a year earlier, while adjusted net income rose to $17.5 million from $9.5 million. That suggests higher sales and cost control are beginning to improve earnings, even though reported net income remained negative. (Neogen Corporation)
Neogen plans to raise R&D investment by about 50% in FY27 and says new products could add $100 million in revenue by FY31. If its innovation and digital food-inspection plans deliver, they could open a longer-term growth path beyond existing tests. (Neogen Corporation, Neogen Corporation)
Neogen still reported a first-quarter net loss of $11.9 million and generated only $4.7 million of free cash flow. Adjusted earnings improved, but the gap shows that the recovery has yet to translate into consistent reported profits and stronger cash generation. (Neogen Corporation)
The 8.1% first-quarter core growth rate included about a 3% benefit from prior-year distributor inventory adjustments and the timing of current-quarter customer orders. Full-year FY26 core growth was only 1.9%, so the rebound may be less robust than the latest headline suggests. (Neogen Corporation, Neogen Corporation)
Debt stood at $780 million at the end of August, leaving the company reliant on a planned Genomics sale to help reduce leverage. That $160 million transaction remains subject to regulatory approval, with Australia and New Zealand having moved their reviews into a second phase. (U.S. Securities and Exchange Commission)
Data summarised monthly by Lightyear AI. Last updated on 26 Oct 2026.
Neogen Financial Performance
Revenues and expenses
Neogen Earnings Performance
Company profitability
Upcoming events
No upcoming events
Neogen News
AllArticlesVideos
Funds containing Neogen
Fund name | Fund size | $NEOG weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.25% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.25% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.25% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.15% |
iShares S&P Small Cap 600£ISP6 | $3.2B | 0.15% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.